Next events

 

16 january 2019  First challenge innovation awards at la pitié salpêtrière hospital

LallianSe provides precision support and actions to healthcare start-ups, scale-ups or SME.

LallianSe has a unique proposition : identifying, building and managing part-time seasoned Experts or Expert teams to drive key responsibilities within life sciences companies.

By building a virtual leadership team, LallianSe

  • helps companies to move from Vision to Strategy to Operational Development
  • fosters their growth in the most time- and cost-effective manner, to deliver maximum value from their innovations
LallianSe is led by seasoned executives in the field of life science venture capital, international development and registration of innovative molecules and medical devices.
Julie Rachline
Helene
Peyro-Saint-Paul
To be announced soon!
Pascale Maisonneuve
Shahrzad Moradi
Julie, Hélène and Pascale combine more than 80 years of experience in regulatory, medical and clinical affairs, product positioning, market access, business development, investing, and corporate governance. Their experiences allow to understand, challenge, and propose adequate solutions with Expert- in-residence team to the life sciences companies ecosystem.

Shahrzad manages the office and the Experts community, providing efficient administrative support and is the little fairy of LallianSe.

Our commitments are:

  • Create and manage tailored Expert-in-residence senior teams that provides strategic and operational support
  • Maximize operational efficacy
  • Invest capital effectively
  • Mesure impact on company performance

LallianSe Experts

LallianSe is built on a community of more than 20 Experts to date, active in 4 strategic domains :

  • Corporate strategy and financing
  • Medical and product strategy, market access
  • Regulatory affairs and quality assurance
  • Business strategy and operations

Our Experts are seasoned executives with the right balance of strategic thinking, operational competencies and international experience, illustrated by significant achievements along their respective careers. They are selected not only on their achievements and skills, but mostly on their philosophy and interpersonal skills.

In addition, LallianSe has established strong ties with a variety of support functions (e.g. biostatistics, communication, HR, finance, IP management, etc.), and has access to a large network of other recognized life sciences experts and KOLs, notably with its offices located at la Pitié Salpêtrière hospital in Paris.

Our Ecosystem

 
 

Selected Ongoing missions

Nissui Pharmaceutical

Nissui Pharmaceutical

Experts missions :

  • Business operations
  • Corporate strategy
  • Special partnership with LallianSe LAB
Advicenne

Advicenne

Experts missions :

  • Corporate strategy
  • Investor relations 
  • Clinical operations 
  • Regulatory affairs
DTAMedical

DTAMedical

Expert mission :

  • Business operations
  • Corporate and financing strategy
LallianSe manages responsibilities for a vast diversity of clients, from early-stage to listed companies, from France to Japan, from medical devices to drugs or services.

Experts team are created based on mandatory execution capabilities, know-how and evaluated achievements, and are driven and managed efficently by a unique chemistry.

 

.

Selected news

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Proteomedix raises 5.2 MCHF in financing round

Proteomedix raises 5.2 MCHF in financing round

ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors.

NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO ANNUAL CONFERENCES

NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO ANNUAL CONFERENCES

Nanobiotix announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, MD, PhD at the ESMO 2018 Congress in Munich

Selected partners   

LallianSe is a unique ecosystem dedicated to life sciences companies and innovators. We strive to accelerate the development of products and services than can change the lives of patients. Join us in the Adventure!

Hôpital de la Salpêtrière

LallianSe LAB offices :
HEUYER Building, 3rd Floor, Hôpital de la Pitié Salpêtrière,
47-83 boulevard de l'hôpital, 75013 Paris, France

4 + 11 =